伊马替尼是一种口服分子靶向疗法，充当酪氨酸激酶抑制剂。蚕为阐明各种化合物的药代动力学和毒性特征提供了一个有前途的实验模型。本研究旨在建立研究伊马替尼在家蚕体内药代动力学的实验范例。对家蚕、人类、小鼠和大鼠的伊马替尼药代动力学参数的比较分析揭示了家蚕和人类之间的最大浓度时间 (Tmax) 和表观清除率值的相似性。然而，蚕和人类之间的消除半衰期 (t1/2) 和表观分布体积的差异仍然分别在 5 倍和 4 倍的范围内。重要的是，在伊马替尼研究中，小鼠的药代动力学参数比大鼠更接近人类。此外，蚕和小鼠表现出相似的 Tmax 和 t1/2 值。这项研究强调了蚕作为药代动力学研究中伊马替尼代谢研究有价值工具的潜力。此外，它强调了蚕在阐明各种分子靶向药物的药代动力学参数方面的适用性，从而促进药物开发和评价的进步。

Imatinib is an oral molecular targeted therapy that acts as a tyrosine kinase inhibitor. Silkworms present a promising experimental model for elucidating the pharmacokinetic and toxicity profiles of various compounds. This study aimed to establish an experimental paradigm for investigating the pharmacokinetics of imatinib in silkworms. A comparative analysis of imatinib pharmacokinetic parameters across silkworms, humans, mice, and rats revealed similarities in time to maximum concentration (Tmax) and apparent clearance values between silkworms and humans. However, differences in elimination half-life (t1/2) and apparent volume of distribution between silkworms and humans remained within 5- and 4-fold ranges, respectively. Importantly, mice demonstrated pharmacokinetic parameters closer to those of humans than rats during imatinib studies. Additionally, silkworms and mice exhibit similar Tmax and t1/2 values. This study highlights the potential of silkworms as valuable tools for investigating imatinib metabolism in pharmacokinetic studies. Furthermore, it underscores the applicability of silkworms in elucidating the pharmacokinetic parameters of various molecular-targeted drugs, thus facilitating advancements in drug development and evaluation.